Related Experiment Video
Updated: Mar 21, 2026
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
15.3K
Moving Mendelian Randomization From Traditional Risk Factors to Molecular Targets for Drug Development and Clinical
Abigail J Berube1,2, Eryn Yu1,2, Pukhraj S Gaheer2,3
1Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Kidney International Reports
|March 20, 2026
Summary
Mendelian randomization uses genetic variation to identify drug targets and predict treatment success, minimizing bias. This approach aids drug discovery and repurposing, particularly in kidney disease research.
Area of Science:
- Genetics
- Pharmacology
- Nephrology
Background:
- Mendelian randomization (MR) uses random allele assortment to assess causal relationships between exposures and outcomes, mitigating bias.
- MR has evolved from studying traditional risk factors to utilizing multiomic data for drug target discovery.
- Advancements like single-cell sequencing and proteomics enhance MR's application in identifying therapeutic targets.
Purpose of the Study:
- To review the principles, applications, and limitations of Mendelian randomization in drug target identification, validation, and repurposing.
- To highlight the role of MR in accelerating drug development, especially within nephrology.
- To discuss emerging methodologies and future directions for MR in drug development.
Main Methods:
- Leveraging genetic variants associated with intermediate phenotypes to infer causality.
- Analyzing large-scale multiomic datasets (genomics, proteomics, transcriptomics).
- Employing techniques such as phenome-wide MR and integrated multiomics.
Main Results:
- MR studies have successfully identified and validated drug targets, with examples including statins, allopurinol, SGLT2 inhibitors, and GLP-1 receptor agonists.
- MR can predict drug efficacy, anticipate adverse effects, and reduce late-stage trial failures.
- Retrospective analyses show concordance between MR findings and clinical trial outcomes.
Conclusions:
- Genetic evidence from MR should be prospectively evaluated for all drug development candidates to overcome the 'translational valley of death'.
- MR offers a powerful framework for accelerating drug development in nephrology by providing robust causal inference.
- Integrated multiomics and advanced analytical methods will further enhance MR's utility in precision medicine and drug discovery.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
75
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
102
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
102
01:27Principles of Pharmacogenetics: Types of Genetic Variants
86
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
86
01:29Pharmacogenetics and Pharmacogenomics: Overview
135
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
135
01:27Pharmacogenetics of Drug Metabolism: Overview
101
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
101
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
65
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65